Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
US HEALTH REGULATORS have denied an application for treating post-traumatic stress disorder (PTSD) with the drug MDMA, commonly known as ecstasy, saying more investigation needed to be done.
The company that submitted the application, Lykos Therapeutics, said in a statement that the Food and Drug Administration (FDA) had requested an additional Phase 3 clinical trial to study MDMA’s “safety and efficacy.”
A panel of experts convened by the FDA to evaluate clinical data on MDMA had overwhelmingly voted in early June to say there was insufficient evidence to prove it was effective.
While unsurprising, the decision announced yesterday represents a blow to advocates of the novel treatment.
“The FDA request for another study is deeply disappointing, not just for all those who dedicated their lives to this pioneering effort, but principally for the millions of Americans with PTSD… who have not seen any new treatment options in over two decades, said Lykos CEO Amy Emerson.
PTSD is a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat or sexual assault.
It affects an estimated five percent of Americans in any given year.
Advertisement
Pharmaceutical treatment options for PTSD are so far limited to two antidepressants that require three months of dosing to take effect, and response rates to the medications have been found to be uneven.
MDMA — methylenedioxymethamphetamine — is a Schedule 1 drug under the Controlled Substances Act, and approving it for medical use would have represented a major shift.
California-based Lykos based its request for regulatory approval on two clinical studies, each of which enrolled around 100 people, to evaluate MDMA used together with other psychological interventions such as talk therapy, against a placebo with talk therapy.
These two studies, published in the prestigious journal Nature Medicine, indicated MDMA was indeed both safe and highly effective at treating PTSD.
But nine out of 11 experts on the FDA panel said available data was not enough to show the treatment was effective, and 10 out of 11 said the benefits did not outweigh the risks.
In a briefing document put together ahead of the meeting, FDA staff raised concerns about Lykos’s clinical trial methodology and criticized the company for not gathering sufficient side effect data.
The company said it will “work diligently in the coming months to address FDA’s concerns and to take advantage of agency processes to resolve scientific disagreements.”
“We intend to work tirelessly and use all available regulatory pathways to find a reasonable and expeditious path forward,” Emerson added.
To embed this post, copy the code below on your site
Close
49 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic.
Please familiarise yourself with our comments policy
here
before taking part.
@Robert Halvey: explain how? Drugs have to go through rigorous testing before being approved. If they get denied it’s usually based on the efficacy of the drug or risk to human life. Do you want drugs going to market that don’t meet regulatory requirements?
@JB Software: Eh, no, they don’t. Most pharmaceuticals are discovered haphazardly, and then they invent an illness to use them to treat unfortunates, with scant benefits for the most part. They don’t even understand why SSRIs happen to alleviate negative symptoms for a minority of users.
@JB Software: The FDA is funded by the companies that need their approval for their smarties. Often, FDA employees get a nice new gig with the aforementioned companies suspiciously soon after products are green-lit.
@Pól Pot: Pharmaceutical companies now invent illness?. Wow I thought I heard crazy before what you just said is a whole new level of crazy. Give me 3 examples of illnesses that pharmaceutical companies have invented to sell a drug?
@Pól Pot: AZT and Oxycontin, my poor fellow with a good night’s rest, and you’ll be right as rain. Give your depressed wife handfuls of benzodiazepines and if she’s still feeling out of sorts, Pervitin.
@JB Software: it’s been proven to be a safe and effective treatment in multiple studies that’s why Australia legalised it last year. The big pharma will try to prevent it from being passed in the US as they stand to lose billions if it does pass
@Pól Pot: they don’t? Wow, I’m going to set up a drug company now and sell smarties as a cure for everything. Thanks for letting me know it was so easy.
@Pól Pot: he was trying to come up with a treatment for migraines. But I’m sure you’ll have a different take to suit your narrative. And I’m not sure what that has got to do with your original rediculous comment earlier about drug companies not having to do any testing.
The most recent drug trial found that more than 86 percent of those who received MDMA achieved a measurable reduction in severity of their symptoms. About 71 percent of participants improved enough that they no longer met the criteria for a PTSD diagnosis.
@JB Software: God you are so naive. I suggest you watch the series Dope Sick, or Faucis HIV treatment in the 80s or the adverse events or deaths reported to VAERS or the UKs Yellow Card system. Pharma regulation is so corrupt. It’s all about the Benjamin’s baby.
@Ger Whelan: you’re not wrong to be sceptical, and for many drugs and diseases you’re right, but you might want to look at Cracked by James Davies and the use of studies around psychiatric drugs SSRIs like Prozac; the FDA makes no secret that companies need to submit a small number of studies showing a drug works, and there is no rule on releasing all the studies conducted. Results not good enough? Fine, finance another 20 trials, one of them is bound to be better
@Alan Kennedy: The real problem – the real cause of the problems – in the US is its privatised health care.
The FDA’s role is to either approve, or otherwise, drugs.
Morphine is highly addictive.
But has its place in health care, as I am thankful for.
So do lots of drugs.
But the entirely profit driven model of US health care is easily abused by the unscrupulous.
And that is what the Sackler family did. They pushed, and pushed, and pushed Oxycotin onto doctors, making claims about its safety, pushing them to prescribe higher and higher doses, to sell more and more, and make obscene profits for themselves.
Oxycotin should have been used with the similar safeguards as Morphine.
And the US justice system has still not held that family to account for what they did. For the countless lives they destroyed.
And until the first such billionaire is properly held to account by the US justice system, then there is a green light for others to repeat what the Sacklers did.
The most recent drug trial found that more than 86 percent of those who received MDMA achieved a measurable reduction in severity of their symptoms. About 71 percent of participants improved enough that they no longer met the criteria for a PTSD diagnosis.
More lost time for invaluable unprecedented therapeutic benefits. Get back to the machine, and don’t forget to keep horsing those SSRIs. You only think you’re not fulfilled.
@Pól Pot: why do you choose to name yourself after someone who murdered 2 million people, or half of the population of his country before Vietnam intervened?
@Shimo F: Surely that’s only prescribed to help children with a specific disorder? It’s not a trend, it helps them focus on their studies where previously they were unable to do much.
@Shimo F: Adderall is hugely beneficial to those that need it, neither it OR mdma will cause one burn their house down for a life of looking for cooper wire in abandoned buildings, like Meth will ffs.
No mention of the “risks” at all. Hardly because they’re minimal, especially when compared with alcohol, tobacco & firearms? All of which are positively encouraged in the good ol’ U, S & A. MDMA wiill never be licensed in the US because it’s readily available and the white ruling class won’t be able to extract huge profits, it’s that simple.
@Jonny Hellzapoppin: I’m actually amazed that someone is stumping up for clinical trials in something they can’t patent.
Perhaps they’re hoping for an exclusive license like the Coca-Cola subsidiary that imports Coca leaves.
Mick O'Dwyer, legendary Kerry GAA manager and footballer, has died aged 88
Updated
1 hr ago
23.1k
27
Live Blog
EU will try launch US tariff negotiations with Lutnick tomorrow, commissioner says
Updated
6 mins ago
14.6k
As it happened
Trump hits EU goods with 20% tariff and rails against foreigners 'pillaging' US
Updated
12 hrs ago
116k
208
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 161 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 110 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 143 partners can use this purpose
Use limited data to select advertising 113 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 83 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 83 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 39 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 35 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 134 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 61 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 74 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 83 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 37 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 46 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 27 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 92 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 99 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 72 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 53 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 88 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 69 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say